Home > Health > Alzheimer’s: Disease Insights and Market Forecasts to 2024 by Pharmascroll

Alzheimer’s: Disease Insights and Market Forecasts to 2024 by Pharmascroll

Added: (Mon May 14 2018)

Pressbox (Press Release) - “Alzheimer’s: Disease Insights and Market Forecasts to 2024” report by Pharmascroll delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Alzheimer’s disease in the US, EU5 (Germany, France, Italy, Spain, UK), and Japan and the historical & forecasted market size, for Alzheimer’s, drug wise in $ sales and patient numbers at global level and in the US, EU5 (Germany, France, Italy, Spain, UK), Australia and Canada till 2024.

Geographies covered:
US
Germany
France
Italy
Spain
UK
Japan
Australia
Canada

Drugs covered
Namenda
Aricept
Exelon
Razadyne
Namzaric
Aducanumab
Crenezumab
Solanezumab
LMTX
Gantenerumab
BAN 2401
Lanabecestat
Elenbecestat
Masican/Masitinib
Nuplazid
JNJ-54861911

Disease Indication Overview:
This section of the report gives the overview of Alzheimer’s disease indication in detail. The section highlights the basic definition, causes and symptoms of disease and details the types of Alzheimer’s disease. Further details on the profile of Alzheimer’s patients, Symptoms experienced by the patients, and disease progression in patients are outlined in the report. The report further highlights the multiple methods through which the patient can be diagnosed for Alzheimer’s disease.

Epidemiology Forecasts to 2024:
This section of the report provides the overview of Alzheimer’s diagnosed prevalent and treated patients in the US, EU5 and Japan market year wise starting from 2015 till 2024. The epidemiology numbers in the report have been derived based on numerous studies, survey reports and views of key opinion leaders.

Drugs Overview and Attribute Analysis:
This part of the report highlights the importance of factors influencing the physician prescription decisions in Alzheimer’s disease including efficacy factors, Tolerability factors, Monitoring requirements and pricing factors.

The report further details the drugs prescribed or expected to be prescribed in Alzheimer’s disease by the physicians in terms of details about the formulation, molecule, mode of administration and mechanism of action of the drugs, their patent and trial details and the expected impact of drug in the Alzheimer’s market.

The report further conducts a detailed drug attribute analysis of the drugs currently prescribed or expected to be prescribed in the disease on the parameters of Efficacy, Safety and Tolerability, Convenience of Monitoring and Dosing and Drug’s coverage of the target patient pool.

Drugs and Market Forecast to 2024:
The report in its last section provides sales and patient numbers forecast for the overall Alzheimer’s market and drug wise forecasts from 2015 till 2024 at Global level and in the US, EU5, Australia and Canada markets. The forecasts are developed based on the detailed drug attribute analysis, conducted by Pharmascroll, as shared in the previous section. It is important to note that the Forecasts conducted by Pharmascroll are not based on simple projections, and are developed meticulously based on a complex forecasting model, owned by Pharmascroll, using multiple assumptions related to launch dates of the products in the market, price of the products, adherence and compliance rates of the products, dosages of the products etc. The forecast models are at the country level and can be developed at the regional level as well.

Why Purchase the Report:
Robust Market and Drug forecast available at country level
Forecast in terms of both $ sales and Patient Numbers
Current and Forecasted Drug treated and Diagnosed Prevalent Patient pool
Detailed Drug Attribute analysis on multiple Clinical Parameters
Multiple Countries coverage
Current Marketed and Pipeline Drugs coverage
Detailed Disease Insights coverage

To read more about the report please visit https://pharmascroll.com/alzheimer-disease-insights-market-forecasts-2024/

To enquire about the report or to make a purchase for the report please write to enquiry@pharmascroll.com

Submitted by:Bhawna Gupta
Disclaimer: Pressbox disclaims any inaccuracies in the content contained in these releases. If you would like a release removed please send an email to remove@pressbox.co.uk together with the url of the release.